ANL (Adlai Nortye) Interest Coverage : No Debt ⁽¹⁾ (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Adlai Nortye's Operating Income for the three months ended in Jun. 2024 was $0.00 Mil. Adlai Nortye's Interest Expense for the three months ended in Jun. 2024 was $0.00 Mil. Adlai Nortye has no debt. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Adlai Nortye's Interest Coverage or its related term are showing as below:

ANL's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 119.59
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Adlai Nortye Interest Coverage Historical Data

The historical data trend for Adlai Nortye's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Adlai Nortye Interest Coverage Chart

Adlai Nortye Annual Data

Trend

Dec21

Dec22

Dec23

Interest Coverage

Adlai Nortye Quarterly Data
	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Jun24
Interest Coverage	Get a 7-Day Free Trial			N/A	-	-	N/A	No Debt

Competitive Comparison of Adlai Nortye's Interest Coverage

For the Biotechnology subindustry, Adlai Nortye's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Adlai Nortye Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Adlai Nortye's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Adlai Nortye's Interest Expense was $-0.79 Mil. Its Operating Income was $-67.55 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.47 Mil.

Adlai Nortye did not have earnings to cover the interest expense.

Adlai Nortye's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Here, for the three months ended in Jun. 2024, Adlai Nortye's Interest Expense was $0.00 Mil. Its Operating Income was $0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Adlai Nortye had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Adlai Nortye (NAS:ANL) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Adlai Nortye Interest Coverage Related Terms

Thank you for viewing the detailed overview of Adlai Nortye's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Adlai Nortye Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902

Website

https://www.adlainortye.com

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.